Treatment-Resistant Depression Patients

Treatment-Resistant Depression (TRD) patients are a clinical population defined by their failure to achieve remission or respond adequately to at least two antidepressant trials of sufficient dose and duration. This population numbers in the tens of millions globally, accounting for approximately one-third of individuals with Major Depressive Disorder.

These patients experience a higher risk of mortality, poor quality of life, and increased rates of anxiety and physical comorbidities compared to non-TRD patients. This results in a significant economic burden, including high direct treatment costs and indirect expenses such as lost wages and hospitalization, with the U.S. national burden estimated at $29–$48 billion annually.

Innovation in this space is critical due to the high demand for healthcare resources and the limitations of traditional monoamine-based antidepressants. While novel therapeutics like esketamine and psychedelic-assisted therapies offer new options, significant gaps in access and reimbursement persist, often requiring multiple failed medication trials before coverage is granted.